Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
ARS Pharmaceuticals, Inc. Market Cap
From what 0 stock analysts predict, the share price for ARS Pharmaceuticals, Inc. (SPRY) might increase by 73.17% in the next year. This is based on a 12-month average estimation for SPRY. Price targets go from $21 to $30. The majority of stock analysts believe SPRY is a sell. Please note analyst price targets are not guaranteed and could be missed completely.
ARS Pharmaceuticals, Inc. has a total of 0 Wall St Analyst ratings. There are 0 buy ratings, 0 ratings, and 0 sell ratings. Since most analysts have a sell consensus rating, the expectation is that ARS Pharmaceuticals, Inc. will perform worse than the market. Investors shouldn't rely purely on analyst ratings; we encourage investors to also take a look at the fundamental and technical analysis in their due diligence.
These are the latest 20 analyst ratings of SPRY.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Josh Schimmer Cantor Fitzgerald | Overweight | $30 | Reiterates | Sep 16, 2024 |
| Josh Schimmer Cantor Fitzgerald | Overweight | $30 | Reiterates | Sep 9, 2024 |
| Josh Schimmer Cantor Fitzgerald | Overweight | $30 | Initiates | Aug 20, 2024 |
| Ryan Deschner Raymond James | Strong Buy | $22 | Upgrade | Aug 13, 2024 |
| Ryan Deschner Raymond James | Outperform | $18 | Initiates | Jul 25, 2024 |
| Andreas Argyrides Wedbush | Outperform | $19 | Reiterates | Mar 11, 2024 |
| Roanna Ruiz Leerink Partners | Outperform | $18 | Upgrade | Mar 5, 2024 |
| Andreas Argyrides Wedbush | Outperform | $13 | Maintains | Nov 13, 2023 |
| Andreas Argyrides Wedbush | Outperform | $5 | Maintains | Sep 21, 2023 |
| Tim Lugo William Blair | Market Perform | Downgrade | Sep 20, 2023 | |
Wedbush | Outperform | Reiterates | Aug 14, 2023 | |
| Andreas Argyrides Wedbush | Outperform | $15 | Maintains | Jun 21, 2023 |
| Andreas Argyrides Wedbush | Outperform | $17 | Reiterates | May 18, 2023 |
| Andreas Argyrides Wedbush | Outperform | $17 | Reiterates | May 12, 2023 |
| Andreas Argyrides Wedbush | Outperform | $17 | Reiterates | May 10, 2023 |
| Andreas Argyrides Wedbush | Outperform | $10 | Initiates | Jan 31, 2023 |
| Tim Lugo William Blair | Outperform | Initiates | Jan 4, 2023 | |
| Roanna Ruiz SVB Leerink | Outperform | $14 | Initiates | Dec 13, 2022 |
Jefferies | Hold | Downgrade | Nov 10, 2022 | |
HC Wainwright & Co. | Buy | Maintains | Nov 4, 2022 |
When did it IPO
2020
Staff Count
23
Country
United States
Sector/Industry
Healthcare/Biotechnology
CEO
Mr. Richard Lowenthal M.B.A., M.S., MSMSEL
Market Cap
$1.27B
In 2023, SPRY generated $30,000 in revenue, which was a decrease of -97.72% from the previous year. This can be seen as a signal that SPRY's business is declining, and its share price could be worth less in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Sun, 15 Sep 2024
Sentiment - NEUTRAL
Source - Accesswire
Summary - The Schall Law Firm is investigating ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) for potential securities law violations related to misleading statements affecting investors.
Why It Matters - The investigation into ARS Pharmaceuticals for potential securities law violations could signal risks of stock price volatility and loss, impacting current and potential investors' decisions.
Mon, 16 Sep 2024
Sentiment - NEUTRAL
Source - Accesswire
Summary - The Schall Law Firm is investigating ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) for potential securities law violations related to misleading statements and undisclosed information.
Why It Matters - The investigation into ARS Pharmaceuticals for potential securities law violations may indicate financial risk, impacting stock performance and investor confidence.
Tue, 17 Sep 2024
Sentiment - NEUTRAL
Source - Accesswire
Summary - The Schall Law Firm is investigating ARS Pharmaceuticals (NASDAQ:SPRY) for potential securities law violations, including misleading statements to investors.
Why It Matters - Investigations into ARS Pharmaceuticals for potential securities law violations may indicate risks of legal repercussions and impact stock value, affecting investor confidence and decisions.
Thu, 12 Sep 2024
Sentiment - NEUTRAL
Source - Accesswire
Summary - The Schall Law Firm is investigating ARS Pharmaceuticals (NASDAQ: SPRY) for potential securities law violations, including false or misleading statements affecting investors.
Why It Matters - The investigation into ARS Pharmaceuticals for potential securities law violations raises concerns about the company's transparency, which could impact stock value and investor confidence.
Fri, 13 Sep 2024
Sentiment - NEUTRAL
Source - Accesswire
Summary - Schall Law Firm is investigating ARS Pharmaceuticals (NASDAQ: SPRY) for potential securities law violations, including false statements and undisclosed information affecting investors.
Why It Matters - The investigation into ARS Pharmaceuticals for potential securities violations could signal financial instability, impacting stock value and investor confidence.
Sat, 14 Sep 2024
Sentiment - NEUTRAL
Source - Accesswire
Summary - The Schall Law Firm is investigating ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) for potential securities law violations, including false statements and undisclosed information affecting investors.
Why It Matters - The investigation into ARS Pharmaceuticals for potential securities law violations raises concerns about the accuracy of its public disclosures, which could impact stock value and investor confidence.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
